In the new studies, the scientists will use ABI's TaqMan Low Density Array, a microfluidic card for real-time PCR, to validate the predictive value of six gene-expression based markers associated with treatment response and survival in diffuse large B cell lymphoma, the most common form of non-Hodgkin's lymphoma.
The initial study was published last April in an article in the New England Journal of Medicine entitled "Prediction of survival in diffuse large B-cell lymphoma based on the expression of six genes." For this study, the researchers used a combination of microarrays, bioinformatics, real-time PCR, and TaqMan gene expression assays, ABI said.